Response-related predictors of survival in CML
The assessment of response to tyrosine kinase inhibitor (TKI) treatment in chronic myeloid leukemia (CML) does not only reflect tumor burden at a given time but has been shown to be linked to long-term survival outcomes as well. Therefore, the quantification of molecular or cytogenetic response as e...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
April 2015
|
| In: |
Annals of hematology
Year: 2015, Volume: 94, Pages: S227-S239 |
| ISSN: | 1432-0584 |
| DOI: | 10.1007/s00277-015-2327-x |
| Online Access: | Verlag, Volltext: http://dx.doi.org/10.1007/s00277-015-2327-x Verlag, Volltext: https://link-springer-com.ezproxy.medma.uni-heidelberg.de/article/10.1007/s00277-015-2327-x 
|
| Author Notes: | Benjamin Hanfstein, Martin C. Müller, Andreas Hochhaus |
| Summary: | The assessment of response to tyrosine kinase inhibitor (TKI) treatment in chronic myeloid leukemia (CML) does not only reflect tumor burden at a given time but has been shown to be linked to long-term survival outcomes as well. Therefore, the quantification of molecular or cytogenetic response as early as 3 months on treatment allows a prognostic stratification of a patient’s individual risk. With competing TKI regimens available, a timely switch of treatment can be considered if unfavorable outcome has to be expected due to early response failure. Numerous studies have demonstrated the association of long-term outcome with early response for first-line treatment with imatinib, with second-generation TKI and for second-line TKI treatment as well. |
|---|---|
| Item Description: | Gesehen am 13.11.2017 |
| Physical Description: | Online Resource |
| ISSN: | 1432-0584 |
| DOI: | 10.1007/s00277-015-2327-x |